| |
Estimates
|
CI
|
p value
|
|---|
|
Total vBMD
|
|
Intercept
|
362.37
|
325.84–398.90
|
< 0.001
|
|
Age
|
− 1.57
|
− 2.23 to − 0.91
|
< 0.001
|
|
Female
|
9.09
|
− 13.47–31.65
|
0.427
|
|
bDMARDs
|
43.52
|
18.18–68.86
|
0.001
|
|
Methotrexate
|
12.12
|
− 17.47–41.71
|
0.420
|
|
Stiffness
|
|
Intercept
|
68.65
|
60.90–76.40
|
< 0.001
|
|
Age
|
− 0.28
|
− 0.42 to − 0.14
|
< 0.001
|
|
Female
|
− 15.66
|
− 20.51 to − 10.82
|
< 0.001
|
|
bDMARDs
|
6.81
|
1.43–12.18
|
0.013
|
|
Methotrexate
|
− 0.67
|
− 7.06–5.72
|
0.835
|
|
Failure load
|
|
Intercept
|
3227.06
|
2879.26–3574.86
|
< 0.001
|
|
Age
|
− 12.77
|
− 19.06 to − 6.49
|
< 0.001
|
|
Female
|
− 732.60
|
− 949.97 to − 515.22
|
< 0.001
|
|
bDMARDs
|
322.23
|
80.84–563.63
|
0.009
|
|
Methotrexate
|
− 4.88
|
− 291.73–281.97
|
0.973
|
- Reference for the change is the no treatment group. Models are adjusted for age, gender, and treatment-gender interaction
- vBMD volumetric bone mineral density, bDMARDs biologic disease-modifying anti-rheumatic drugs, CI confidence interval
